Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer

Breast Cancer Research

Volumn 2, Issue 5, 2000, Pages 335-344

  Katzenellenbogen, B S ^a   Katzenellenbogen, J A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Coactivators; Corepressors; Estrogen receptor; Ligands for estrogen receptors; Selective estrogen receptor modulators

Indexed keywords

CANCER GROWTH FACTOR; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HYDROXYTAMOXIFEN; LIGAND; PROTEIN KINASE; PYRAZOLE DERIVATIVE; RALOXIFENE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REGULATOR PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ESTROGEN;

BIOCHEMISTRY; BIOMEDICINE; BREAST CANCER; COMPLEX FORMATION; CONTROLLED STUDY; CYTOLOGY; DNA RESPONSIVE ELEMENT; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG TARGETING; ESTROGEN RESPONSIVE ELEMENT; FEMALE FERTILITY; HORMONE SUBSTITUTION; MENOPAUSE; MOLECULAR BIOLOGY; MORPHOLOGY; PHOSPHORYLATION; RECEPTOR AFFINITY; REGULATORY MECHANISM; REVIEW; TISSUE DISTRIBUTION; TISSUE SPECIFICITY; TRANSACTIVATION; TRANSCRIPTION REGULATION; ANIMAL; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FEMALE; GENETIC TRANSCRIPTION; HUMAN; METABOLISM; PHYSIOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; LIGANDS; PROMOTER REGIONS, GENETIC; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 0034466972     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr78     Document Type: Review

References (105)

1. The molecular pharmacology of SERMs
2. Selective estrogen receptor modulators (SERMS)
3. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
4. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation
5. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones
6. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
7. ERβ: Identification and characterization of a novel human estrogen receptor
8. Estrogen receptor transcription and transactivation: Basic aspects of estrogen action
9. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
10. Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta
11. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation
12. Transcription activation by the human estrogen receptor subtype β (ERβ) studied with ERβ and ERα receptor chimeras
13. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β
14. Novel ligands that function as selective estrogens or anti-estrogens for estrogen receptor-α or estrogen receptor-β
15. Acyclic amides as estrogen receptor ligands
16. Estrogen receptor subtype-selective ligands: Asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl-5,6,11,12-tetrahydrochrysenes
17. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
18. Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding
19. Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens
20. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
21. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: Correlations with DNA and coregulator interactions and receptor conformational changes
22. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation
23. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta
24. Peptide antagonists of the human estrogen receptor
25. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: Discovery of peptide antagonists of estrogen receptors alpha and beta
26. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, Cp-336156, a diaryltetrahydronaphthalene
27. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone
28. 8,9 dehydroestrone sulfate in postmenopausal women
29. Interaction of human estrogen receptors alpha and beta with the same naturally occurring estrogen response elements
30. Allosteric effects of DNA on transcriptional regulators
31. Estrogen response elements function as allosteric modulators of estrogen receptor conformation
32. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
33. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions
34. The quinone reductase gene: A unique estrogen receptor-regulated gene that is activated by antiestrogens
35. Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-α and estrogen receptor-β
36. Identification of an estrogen response element activated by metabolites of 17-β-estradiol and raloxifene
37. The human estrogen receptor has two independent transcriptional nonacidic activation functions
38. The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell specific
39. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
40. Segregation of steroid receptor coactivator-1 from steroid receptors in mammary epithelium
41. Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor
42. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator
43. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action
44. Nuclear receptor coactivators and corepressors
45. Nuclear receptor coactivators
46. Nuclear receptor coregulators: Cellular and molecular biology
47. The coregulator exchange in transcriptional functions of nuclear receptors
48. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor
49. Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression
50. Sequence and characterization of a coactivator for the steroid hormone receptor super family
51. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens
52. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
53. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
54. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
55. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
56. Transcription factor-specific requirements for coactivators and their acetyltransferase functions
57. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor alpha and estrogen receptor beta: Correlations with biological character and distinct differences among SRC coactivator family members
58. Estrogen receptors α and β form heterodimers on DNA
59. Human estrogen receptor beta binds DNA in a similar to and dimerizes with estrogen receptor alpha
60. Expression of estrogen receptor β messenger RNA variant in breast cancer
61. Expression of estrogen receptor-β in human breast tumors
62. Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis
63. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors
64. The estrogen receptor beta-isoform (ERβ) of the human estrogen receptor modulates ER alpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
65. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen
66. Estrogen receptor mutation in tamoxifen-resistant breast cancer
67. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice
68. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor
69. Antiestrogens: Mechanisms of action and resistance in breast cancer
70. Molecular mechanisms of resistance to tamoxifen therapy in breast cancer
71. Mechanisms of tamoxifen resistance
72. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-1
73. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen-selectivity and promoter-dependence
74. Coupling of dual signaling pathways: Epidermal growth factor action involves the estrogen receptor
75. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
76. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
77. Steroid hormone receptors and their regulation by phosphorylation
78. Cholera-toxin-enhanced growth of human breast cancer cell lines in vitro and in vivo: Interaction with estrogen
79. cAMP stimulates growth and morphogenesis of mouse mammary ducts
80. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1
81. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor
82. Phosphorylation of the human estrogen receptor: Identification of hormone-regulated sites and examination of their influence on transcriptional activity
83. Phosphorylation of the human oestrogen receptor: Identification of a phosphorylation site required for transactivation
84. Identification of phosphorylation sites in the mouse oestrogen receptor
85. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167
86. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase
87. Estrogen receptor null mice: What have we learned and where will they lead us?
88. + exchanger regulatory factor
89. Properties of a purified estradiol-dependent calf uterus tyrosine kinase
90. Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element
91. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein
92. Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine
93. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer
94. The function of estrogen receptor tyrosine 537 in hormone binding, DNA binding and transactivation
95. Ligand-independent activation of the estrogen receptors α and β by mutations of a conserved tyrosine can be abolished by antiestrogens
96. Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators
97. Protein tyrosine phosphorylation and estradiol action
98. Cell signaling and estrogens in female rat osteoblasts: A possible involvement of unconventional nonnuclear receptors
99. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium
100. Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain
101. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ERα and ERβ expressed in chinese hamster ovary cells
102. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells
103. Rapid actions of estrogens in GH3/B6 pituitary tumor cells via a plasma membrane version of estrogen receptor-alpha
104. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding
105. 125] bovine serum albumim conjugate